- Home
- SRTS vs AVTX Comparison
SRTS vs AVTX Comparison
Compare SRTS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- AVTX
- Stock Information
- Founded
- SRTS 2010
- AVTX 2011
- Country
- SRTS United States
- AVTX United States
- Employees
- SRTS N/A
- AVTX N/A
- Industry
- SRTS Medical/Dental Instruments
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- AVTX Health Care
- Exchange
- SRTS Nasdaq
- AVTX Nasdaq
- Market Cap
- SRTS 110.3M
- AVTX 88.4M
- IPO Year
- SRTS 2016
- AVTX 2015
- Fundamental
- Price
- SRTS $5.38
- AVTX $8.44
- Analyst Decision
- SRTS Strong Buy
- AVTX Strong Buy
- Analyst Count
- SRTS 2
- AVTX 4
- Target Price
- SRTS $13.00
- AVTX $33.00
- AVG Volume (30 Days)
- SRTS 562.9K
- AVTX 36.6K
- Earning Date
- SRTS 02-05-2025
- AVTX 03-28-2025
- Dividend Yield
- SRTS N/A
- AVTX N/A
- EPS Growth
- SRTS 1266.06
- AVTX N/A
- EPS
- SRTS 0.41
- AVTX N/A
- Revenue
- SRTS $41,807,000.00
- AVTX $820,000.00
- Revenue This Year
- SRTS $9.09
- AVTX N/A
- Revenue Next Year
- SRTS $22.30
- AVTX N/A
- P/E Ratio
- SRTS $13.64
- AVTX N/A
- Revenue Growth
- SRTS 71.31
- AVTX N/A
- 52 Week Low
- SRTS $2.91
- AVTX $4.24
- 52 Week High
- SRTS $9.33
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- SRTS 37.03
- AVTX 57.77
- Support Level
- SRTS $5.41
- AVTX $6.81
- Resistance Level
- SRTS $5.88
- AVTX $8.00
- Average True Range (ATR)
- SRTS 0.50
- AVTX 0.56
- MACD
- SRTS -0.12
- AVTX 0.03
- Stochastic Oscillator
- SRTS 0.54
- AVTX 81.99
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).